BioCryst Pharmaceuticals reached a significant milestone in 2025, reporting its first full-year profitability in company history while substantially growing its hereditary angioedema (HAE) treatment portfolio. The company's lead product ORLADEYO generated $601.8 million in net revenue for the year, representing a 38% increase compared to 2024. This strong performance reflects expanding market adoption and reflects the company's success in establishing ORLADEYO as a key treatment option in the HAE space.
The company's growth trajectory was bolstered by regulatory and strategic developments during the period. BioCryst secured FDA approval for ORLADEYO oral pellets, extending the medication's availability to pediatric patients ages 2-11 and opening new treatment opportunities in the younger patient population. Additionally, the company completed its acquisition of Astria Therapeutics, bringing navenibart into its HAE portfolio and diversifying its product pipeline with a complementary treatment mechanism.
Looking ahead to 2026, BioCryst maintained its ORLADEYO revenue guidance at $625-645 million, signaling confidence in continued market growth despite divesting its European ORLADEYO business. The company reported record operating profit for 2025, demonstrating improved operational efficiency and financial discipline as it navigates the evolving competitive landscape in the HAE treatment market.